Halozyme Therapeutics CEO Helen Torley's 2020 pay rises 11% to $6.5M
Halozyme Therapeutics reports 2020 executive compensation
By ExecPay News
Published: March 26, 2021
Halozyme Therapeutics reported fiscal year 2020 executive compensation information on March 26, 2021.
In 2020, five executives at Halozyme Therapeutics received on average a compensation package of $2.8M, a 8% decrease compared to previous year.
Average pay of disclosed executives at Halozyme Therapeutics
Helen I. Torley, Chief Executive Officer, received $6.5M in total, which increased by 11% compared to 2019. 38% of Torley's compensation, or $2.5M, was in stock awards. Torley also received $712K in non-equity incentive plan, $2.5M in option awards, $791K in salary, as well as $15K in other compensation.
For fiscal year 2020, the median employee pay was $223,441 at Halozyme Therapeutics. Therefore, the ratio of Helen I. Torley's pay to the median employee pay was 29 to one.
Elaine D. Sun, Chief Financial Officer, received a compensation package of $3.4M. 45% of the compensation package, or $1.5M, was in stock awards.
Michael J. LaBarre, Senior Vice President, Chief Technical Officer, earned $2M in 2020.
Masaru Matsuda, General Counsel, received $1.7M in 2020.
Laurie D. Stelzer, Chief Financial Officer, earned $171K in 2020, a 92% decrease compared to previous year.
Related executives
Helen Torley
Halozyme Therapeutics
Chief Executive Officer
Elaine Sun
Halozyme Therapeutics
Chief Financial Officer
Laurie Stelzer
Halozyme Therapeutics
Chief Financial Officer
Masaru Matsuda
Halozyme Therapeutics
General Counsel
Michael LaBarre
Halozyme Therapeutics
Senior Vice President, Chief Technical Officer
You may also like
Source: SEC filing on March 26, 2021.